Linked Life Data

8139476

Source:http://linkedlifedata.com/resource/pubmed/id/8139476

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1994-4-26
pubmed:abstractText
The effect of tetrahydrolipstatin (THL), a recently developed pancreatic lipase inhibitor, on fasting plasma lipid levels and postprandial lipoprotein and retinyl palmitate (RP) metabolism was studied in 17 hyperlipidemic subjects, using an oral RP fat load (8 hours, 50 g fat/m2). During therapy with THL, fasting plasma cholesterol, low-density lipoprotein (LDL) cholesterol, and apolipoprotein (apo) B concentrations decreased by 8% (P = .006), 9% (P = .002), and 10% (P = .002), respectively. The postprandial plasma triglyceridemia, which was expressed as the area under the 8-hour triglyceride (TG) curve, improved by 27% during THL therapy (P = .04) without changes in fasting plasma TG or high-density lipoprotein (HDL) cholesterol levels. The improved postprandial triglyceridemia was accompanied by a 19% reduction in circulating levels of chylomicrons and chylomicron remnants, determined by the decreased areas under the 8-hour RP curves. The most likely mechanisms involved are decreased formation of chylomicrons by a decrease of intestinal TG absorption as a consequence of THL treatment, as well as reduced delivery of dietary lipid and fatty acids to the liver and subsequent upregulation of hepatic LDL receptors. In agreement with the latter mechanism, the decrease in postprandial lipemia expressed as delta area under the TG curve was significantly related to the decrease (delta) in LDL cholesterol level during THL treatment (r = .81, P = .0001). The present data indicated that pancreatic lipase inhibition improved postprandial lipoprotein metabolism, which in turn resulted in lower plasma total and LDL cholesterol concentrations.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0026-0495
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
293-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:8139476-Administration, Oral, pubmed-meshheading:8139476-Apolipoproteins B, pubmed-meshheading:8139476-Cholesterol, HDL, pubmed-meshheading:8139476-Cholesterol, LDL, pubmed-meshheading:8139476-Chylomicrons, pubmed-meshheading:8139476-Dose-Response Relationship, Drug, pubmed-meshheading:8139476-Double-Blind Method, pubmed-meshheading:8139476-Eating, pubmed-meshheading:8139476-Female, pubmed-meshheading:8139476-Humans, pubmed-meshheading:8139476-Hyperlipidemias, pubmed-meshheading:8139476-Intestinal Absorption, pubmed-meshheading:8139476-Lactones, pubmed-meshheading:8139476-Linear Models, pubmed-meshheading:8139476-Lipase, pubmed-meshheading:8139476-Lipids, pubmed-meshheading:8139476-Lipoproteins, LDL, pubmed-meshheading:8139476-Male, pubmed-meshheading:8139476-Middle Aged, pubmed-meshheading:8139476-Pancreas, pubmed-meshheading:8139476-Triglycerides, pubmed-meshheading:8139476-Vitamin A
pubmed:year
1994
pubmed:articleTitle
Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor.
pubmed:affiliation
Department of Internal Medicine, Academic Hospital, Utrecht, The Netherlands.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study